Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EPS (Basic) (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed EPS (Basic) for 12 consecutive years, with -$0.09 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) fell 228.57% year-over-year to -$0.09, compared with a TTM value of $0.36 through Sep 2025, up 111.76%, and an annual FY2024 reading of $0.38, up 3900.0% over the prior year.
  • EPS (Basic) was -$0.09 for Q3 2025 at CytomX Therapeutics, down from -$0.05 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.27 in Q1 2025 and bottomed at -$0.91 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.15, with a median of -$0.08 recorded in 2024.
  • Peak annual rise in EPS (Basic) hit 2200.0% in 2024, while the deepest fall reached 300.0% in 2024.
  • Year by year, EPS (Basic) stood at -$0.91 in 2021, then surged by 85.71% to -$0.13 in 2022, then soared by 107.69% to $0.01 in 2023, then soared by 2200.0% to $0.23 in 2024, then plummeted by 139.13% to -$0.09 in 2025.
  • Business Quant data shows EPS (Basic) for CTMX at -$0.09 in Q3 2025, -$0.05 in Q2 2025, and $0.27 in Q1 2025.